Cochlear Limited

DGAP-News: Precisis concludes funding round of €20 million for its bioelectric brain stimulation system

Thursday, October 14, 2021 - 12:08pm

Heidelberg, Germany, [14 October 2021] - Precisis AG, based in Heidelberg, announced that it has successfully concluded a funding round of 20 million with Cochlear Limited.

Key Points: 
  • Heidelberg, Germany, [14 October 2021] - Precisis AG, based in Heidelberg, announced that it has successfully concluded a funding round of 20 million with Cochlear Limited.
  • Precisis is a medical technology company that develops minimally invasive brain stimulation methods to relieve epilepsy patients from their symptoms.
  • The additional funding will be used to support ongoing clinical studies and to further advance EASEE(R), an implantable bioelectric brain stimulation system that explores novel approaches to treating epilepsy.
  • Angela Liedler, MD, CEO of Precisis AG, is thrilled: "This funding round is an important step in the advancement of bioelectric brain stimulation.

Sensorion Reports 2021 First Half Results

Monday, September 27, 2021 - 6:30am

Many elements of Sensorions strategic planning came together in a successful first half of 2021.

Key Points: 
  • Many elements of Sensorions strategic planning came together in a successful first half of 2021.
  • Since not all of the patients have yet completed their 28-day end of treatment visit, Sensorion will continue the recruitment until the end of October 2021.
  • Following this initial success, Sensorion and Cochlear announced the initiation of a Phase 1 clinical trial of SENS-401 (Arazasetron) in patients scheduled for cochlear implantation on September 8, 2021.
  • The study will be sponsored by Sensorion and the proposed design is expected to be submitted to regulatory authorities during H2 2021 (see post-closing events).

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination With Cochlear Implantation

Wednesday, September 8, 2021 - 7:30am

We are excited Cochlear has decided to work with us to further develop SENS-401 in clinical studies said Nawal Ouzren, CEO of Sensorion.

Key Points: 
  • We are excited Cochlear has decided to work with us to further develop SENS-401 in clinical studies said Nawal Ouzren, CEO of Sensorion.
  • The results of Sensorions in vivo preclinical studies on the use of SENS-401 in conjunction with cochlear transplantation were encouraging.
  • The new clinical study will explore the potential efficacy of SENS-401 in combination with cochlear implants.
  • We believe the combination of cochlear implant technology and pharma therapies has the potential to enhance patient outcomes in terms of preservation of residual hearing and speech understanding.

Cochlear obtains FDA approval of Kanso 2 Sound Processor, first off-the-ear cochlear implant sound processor with direct smartphone connectivity

Monday, July 6, 2020 - 1:06pm

The approval of the Cochlear Nucleus Kanso 2 Sound Processor, Nucleus 7 Sound Processor for Nucleus 22 Implant recipients and Custom Sound Pro fitting softwarereflects Cochlear's ongoing commitment to innovation in hearing technology, providing access to smartphone connectivity and helping to improve hearing performance, and enhancing the cochlear implant fitting experience for hearing health professionals.

Key Points: 
  • The approval of the Cochlear Nucleus Kanso 2 Sound Processor, Nucleus 7 Sound Processor for Nucleus 22 Implant recipients and Custom Sound Pro fitting softwarereflects Cochlear's ongoing commitment to innovation in hearing technology, providing access to smartphone connectivity and helping to improve hearing performance, and enhancing the cochlear implant fitting experience for hearing health professionals.
  • The Kanso 2 Sound Processor is the world's smallest1 off-the-ear cochlear implant sound processor, and it is the first and only off-the-ear cochlear implant sound processor to offer direct streaming from compatible Appleor Android devices.
  • The Kanso 2 Sound Processor also features the highest possible water resistance rating for any off-the-ear cochlear implant sound processor, giving users the freedom to live an active lifestyle.
  • At commercial availability, the Kanso 2 Sound Processor is compatible with Cochlear N24, CI24RE, CI500, Profile and Profile Plus Series Implants.

Cochlear Implants Market Size Worth $3.4 Billion by 2026 | CAGR: 10.5%: Grand View Research, Inc.

Thursday, February 20, 2020 - 9:05am

The cochlear implants market is anticipated to witness significant growth during the forecast period, which can be attributed to a favorable reimbursement scenario, rising awareness about hearing aids, and increasing adoption of implants.

Key Points: 
  • The cochlear implants market is anticipated to witness significant growth during the forecast period, which can be attributed to a favorable reimbursement scenario, rising awareness about hearing aids, and increasing adoption of implants.
  • Increasing demand, ability to recognize the speech in noise, and good reimbursement are the key factors expected to drive the market during the forecast period.
  • In June 2019, Cochlear Limited received the approval from the U.S. FDA for its Cochlear Nucleus Profile Plus Series Cochlear Implant.
  • Grand View Research has segmented the cochlear implants market by type of fitting, by end use, and region:
    Cochlear Implants Type of Fitting Outlook (Market Revenue in USD Million, 2015 - 2026)
    Cochlear Implants End Use Outlook (Market Revenue in USD Million, 2015 - 2026)
    Cochlear Implants Regional Outlook (Market Revenue in USD Million, 2015 - 2026)

Cochlear Implants Market Size Worth $3.4 Billion by 2026 | CAGR: 10.5%: Grand View Research, Inc.

Thursday, February 20, 2020 - 9:05am

The cochlear implants market is anticipated to witness significant growth during the forecast period, which can be attributed to a favorable reimbursement scenario, rising awareness about hearing aids, and increasing adoption of implants.

Key Points: 
  • The cochlear implants market is anticipated to witness significant growth during the forecast period, which can be attributed to a favorable reimbursement scenario, rising awareness about hearing aids, and increasing adoption of implants.
  • Increasing demand, ability to recognize the speech in noise, and good reimbursement are the key factors expected to drive the market during the forecast period.
  • In June 2019, Cochlear Limited received the approval from the U.S. FDA for its Cochlear Nucleus Profile Plus Series Cochlear Implant.
  • Grand View Research has segmented the cochlear implants market by type of fitting, by end use, and region:
    Cochlear Implants Type of Fitting Outlook (Market Revenue in USD Million, 2015 - 2026)
    Cochlear Implants End Use Outlook (Market Revenue in USD Million, 2015 - 2026)
    Cochlear Implants Regional Outlook (Market Revenue in USD Million, 2015 - 2026)

The Asia Pacific cochlear implants market is expected to reach US$ 833.1 Mn in 2027 from US$ 291.6 Mn in 2018

Wednesday, February 19, 2020 - 8:30pm

NEW YORK, Feb. 19, 2020 /PRNewswire/ -- The Asia Pacific cochlear implants market is expected to reach US$ 833.1 Mn in 2027 from US$ 291.6 Mn in 2018.

Key Points: 
  • NEW YORK, Feb. 19, 2020 /PRNewswire/ -- The Asia Pacific cochlear implants market is expected to reach US$ 833.1 Mn in 2027 from US$ 291.6 Mn in 2018.
  • On the other hand, the growing medical tourism industry in Asia Pacific countries is expected to have a positive effect on the growth of the Asia Pacific cochlear implants market in the coming years.
  • Thus the growing prevalence of hearing loss in the Asia Pacific region is likely to demand cochlear implants.
  • Asia Pacific cochlear implants market is segmented by type of fitting and end-user.Based on the type of fitting, the cochlear implant market is categorized as unilateral implantation and bilateral implantation.

OneTrust Expands in Australia and New Zealand with New Melbourne Office and Integrated ANZ Privacy Laws into Industry Leading Privacy Management Platform

Sunday, August 19, 2018 - 11:00pm

MELBOURNE, Australia, Aug. 19,2018 /PRNewswire/ --OneTrust, the global leader in privacy management and marketing compliance today announced its expansion in Australia and New Zealand.

Key Points: 
  • MELBOURNE, Australia, Aug. 19,2018 /PRNewswire/ --OneTrust, the global leader in privacy management and marketing compliance today announced its expansion in Australia and New Zealand.
  • Sydney-based Cochlear Limited, the global leader in implantable hearing solutions, uses OneTrust technologies for privacy compliance in ANZ and across the globe.
  • Australia just named a new privacy commissioner, and recently amended the Australian Privacy Act introducing mandatory notification procedures for data breaches.
  • OneTrust is co-headquartered in Atlanta, GA and in London, UK, with additional offices in Munich, Bangalore, Hong Kong and Melbourne.